RT Journal Article
SR Electronic
T1 Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial’
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP annrheumdis-2021-220759
DO 10.1136/annrheumdis-2021-220759
A1 Yan Zhao
A1 Jin-Xian Huang
YR 2021
UL http://ard.bmj.com/content/early/2021/06/25/annrheumdis-2021-220759.abstract
AB